Cargando…

Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure

Chimeric antigen receptor (CAR) T cell therapies have resulted in profound clinical responses in the treatment of CD19-positive hematological malignancies, but a significant proportion of patients do not respond or relapse eventually. As an alternative to CAR T cells, T cells can be engineered to ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wachsmann, Tassilo L. A., Wouters, Anne K., Remst, Dennis F. G., Hagedoorn, Renate S., Meeuwsen, Miranda H., van Diest, Eline, Leusen, Jeanette, Kuball, Jürgen, Falkenburg, J. H. Frederik, Heemskerk, Mirjam H. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812760/ https://www.ncbi.nlm.nih.gov/pubmed/35127255 http://dx.doi.org/10.1080/2162402X.2022.2033528

Ejemplares similares

Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma
por: Wachsmann, Tassilo L. A., et al.
Publicado: (2023)

T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion
por: Morton, Laura T, et al.
Publicado: (2022)

Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain
por: Meeuwsen, Miranda H., et al.
Publicado: (2023)

A library of cancer testis specific T cell receptors for T cell receptor gene therapy
por: de Rooij, Marije A.J., et al.
Publicado: (2022)

A library of cancer testis specific T cell receptors for T cell receptor gene therapy
por: de Rooij, Marije A.J., et al.
Publicado: (2023)

Extracellular Domains of CD8α and CD8ß Subunits Are Sufficient for HLA Class I Restricted Helper Functions of TCR-Engineered CD4(+) T Cells
por: van Loenen, Marleen M., et al.
Publicado: (2013)

PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer
por: van Amerongen, Rosa A., et al.
Publicado: (2023)

A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer
por: Jahn, Lorenz, et al.
Publicado: (2016)

An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML
por: van der Lee, Dyantha I., et al.
Publicado: (2021)

Reprogramming of Virus-specific T Cells into Leukemia-reactive T Cells Using T Cell Receptor Gene Transfer
por: Heemskerk, Mirjam H.M., et al.
Publicado: (2004)

Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential
por: van Amerongen, Rosa A., et al.
Publicado: (2023)

Generation of CD20-specific TCRs for TCR gene therapy of CD20(low) B-cell malignancies insusceptible to CD20-targeting antibodies
por: Jahn, Lorenz, et al.
Publicado: (2016)

A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies
por: Rosskopf, Sandra, et al.
Publicado: (2018)

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers
por: van Diest, Eline, et al.
Publicado: (2023)

SARS-CoV-2-specific CD4(+) and CD8(+) T cell responses can originate from cross-reactive CMV-specific T cells
por: Pothast, Cilia R, et al.
Publicado: (2022)

WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma
por: van Amerongen, Rosa A, et al.
Publicado: (2022)

Serpin B9 controls tumor cell killing by CAR T cells
por: Kimman, Thomas, et al.
Publicado: (2023)

Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells
por: Kierkels, Guido J.J., et al.
Publicado: (2021)

TCR-like CARs and TCR-CARs targeting neoepitopes: an emerging potential
por: Poorebrahim, Mansour, et al.
Publicado: (2021)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

Joining Forces for Cancer Treatment: From “TCR versus CAR” to “TCR and CAR”
por: Teppert, Karin, et al.
Publicado: (2022)

PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy
por: Luk, Sietse J, et al.
Publicado: (2018)

Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain
por: Kuball, Jürgen, et al.
Publicado: (2009)

Chimeric Antigen Receptor (CAR) Regulatory T-Cells in Solid Organ Transplantation
por: Gille, Ilse, et al.
Publicado: (2022)

Challenges of CAR- and TCR-T cell–based therapy for chronic infections
por: Bertoletti, Antonio, et al.
Publicado: (2020)

HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study
por: van Balen, Peter, et al.
Publicado: (2020)

The Enigmatic Nature of the TCR-pMHC Interaction: Implications for CAR-T and TCR-T Engineering
por: Shevyrev, D. V., et al.
Publicado: (2022)

Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
por: van Diest, Eline, et al.
Publicado: (2021)

Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies
por: Kroonen, Jessie S., et al.
Publicado: (2023)

CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins
por: Jost, Christian, et al.
Publicado: (2020)

TCR-Like CAR-T Cells Targeting MHC-Bound Minor Histocompatibility Antigens
por: Akatsuka, Yoshiki
Publicado: (2020)

Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells
por: Hiltensperger, Michael, et al.
Publicado: (2023)

Therapeutic targeting of PRAME with (mTCR)CAR T cells in acute myeloid leukemia
por: Kirkey, Danielle C., et al.
Publicado: (2022)

The Role of γδ T Cells as a Line of Defense in Viral Infections after Allogeneic Stem Cell Transplantation: Opportunities and Challenges
por: Janssen, Anke, et al.
Publicado: (2022)

Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer
por: Scholten, Kirsten BJ, et al.
Publicado: (2011)

P74. A Good Manufacturing Practice procedure to generate therapeutic numbers of highly pure anti-leukaemic virus-specific T-cells
por: van Loenen, MM, et al.
Publicado: (2014)

CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function
por: Sahillioglu, Ali Can, et al.
Publicado: (2021)

Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control
por: Cai, Yihua, et al.
Publicado: (2021)

Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
por: MacLeod, Daniel T., et al.
Publicado: (2017)

A Costimulatory CAR Improves TCR-based Cancer Immunotherapy
por: Omer, Bilal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mmjta95ifn4at4a8rcjraqkn5t